SI
CHRS icon

Scout Investments’s Coherus Oncology CHRS Stock Holding History

Scout Investments’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-614,307
Closed -$2.21M – 209
2023
Q3 		$2.21M Sell
614,307
-17,829
-3% -$82.3K 0.05% 209
2023
Q2 		$2.86M Sell
632,136
-18,814
-3% -$111K 0.06% 208
2023
Q1 		$4.45M Sell
650,950
-7,688
-1% -$59.7K 0.09% 190
2022
Q4 		$5.22M Sell
658,638
-10,748
-2% -$82.7K 0.11% 185
2022
Q3 		$6.43M Sell
669,386
-18,940
-3% -$192K 0.13% 175
2022
Q2 		$4.98M Buy
688,326
+92,739
+16% +$806K 0.1% 192
2022
Q1 		$7.69M Sell
595,587
-773
-0.1% -$9.83K 0.12% 181
2021
Q4 		$9.52M Sell
596,360
-13,378
-2% -$234K 0.14% 193
2021
Q3 		$9.8M Sell
609,738
-15,831
-3% -$232K 0.15% 195
2021
Q2 		$8.65M Buy
625,569
+74,618
+14% +$1.06M 0.13% 210
2021
Q1 		$8.05M Buy
+550,951
New +$9.35M 0.12% 234

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scout Investments's CHRS Position: Q4 2023 in Review

Scout Investments sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 614,307 shares — an estimated $2.21M sold.

Scout Investments first reported a position in CHRS in Q1 2021 and held it in 11 quarters. The position peaked at $9.8M in Q3 2021. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Scout Investments reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Scout Investments sold 614,307 Coherus Oncology shares in Q4 2023, an estimated $2.21M.
  • Scout Investments first reported a position in Coherus Oncology in Q1 2021 and held it in 11 quarters.
  • Scout Investments's Coherus Oncology position peaked at $9.8M in Q3 2021.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Scout Investments's 13F filing for Q4 2023, filed 13 Feb 2024.